Glucagon‐like‐peptide‐1 receptor agonists versus dipeptidyl peptidase‐4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study

Glucagon‐like‐peptide‐1 receptor agonists versus dipeptidyl peptidase‐4 inhibitors and cardiovascular outcomes in diabetes in relation to achieved glycemic control. A Danish nationwide study

Abstract Aim To compare the cardiovascular preventive effect associated with glucagon‐like‐peptide‐1 receptor agonists (GLP‐1 RA) versus dipeptidyl peptidase‐4 inhibitors (DPP‐4i) according to the achieved target level of glycated hemoglobin (HbA1c). Methods We used retrospective Danish registries t...

Full description

Bibliographic Details
Main Authors: Bochra Zareini, Katrine Kold Sørensen, Ulrik Pedersen‐Bjergaard, Emil Loldrup Fosbøl, Lars Køber, Christian Torp‐Pedersen
Format: Article
Language:English
Published: Wiley 2024-06-01
Series:Journal of Diabetes
Subjects:
DPP‐4i
GLP‐1 RA
glycemic control
HbA1c
MACE
myocardial infarction
Online Access:https://doi.org/10.1111/1753-0407.13560

Internet

https://doi.org/10.1111/1753-0407.13560

Similar Items